
    
      This is an open-label, randomized, 2-way crossover study to evaluate the PK/PD and safety of
      TA-7284 in patients with type 2 diabetes mellitus who have moderate renal impairment relative
      to patients with type 2 diabetes mellitus who have normal renal function. The patients will
      receive both TA-7284-Low and TA-7284-High orally alone in either Period 1 or 2.
    
  